Time Cap Pharma Labs Private Limited, a active private limited company, was established on 19 February 1988 in Hyderabad, Telangana, India. Engaging in industrial chemicals within the manufacturing sector, it holds CIN: U24232TG1988PTC008333. Registered under ROC Roc Hyderabad. it is unlisted. It has an authorized capital of ₹1.00 Cr and a paid-up capital of ₹4.16 M.
Formerly known as Time Cap Pharma Labs Ltd, Time Cap Pharma Labs Pvt Ltd. It upholds a compliant status. Employing 2 professional, Its leadership includes Venkata Satya Swathi Kantamani (Whole-Time Director), Sadasiva Rao Nannapaneni (Director), Adinarayana Madineedi (Director). Past directors included Sadasiva Rao Nannapaneni, Adinarayana Madineedi, Pulla Rao Jasti. It holds ₹3.08 Cr open charges and no settled loans. Its latest AGM occurred on 27 September 2025, with the balance sheet filed on 31 March 2025. It is based at Natco House , Road No.2 Banjara Hills, Hyderabad, Telangana.
U24232TG1988PTC008333
008333
19 February 1988
₹1.00 Cr
₹4.16 M
Roc Hyderabad
Unlisted
Active
Explore comprehensive insights into Time Cap Pharma Labs Private Limited — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.
Access Report
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Venkata Satya Swathi Kantamani | Whole-Time Director | 30 Sep 2024 | Current |
| Sadasiva Rao Nannapaneni | Director | 30 Apr 2009 | Current |
| Adinarayana Madineedi | Director | 31 Jan 2019 | Current |
| Anand Babu Tummala | Director | 29 Apr 2000 | Current |
| Name | Designation | Cessation | Status |
|---|---|---|---|
| Pramod Abcsdd | Additional Director | 29 Sep 2009 | Past |
| Pramod Abcsdd | Additional Director | 30 Sep 2019 | Past |
| Pramod Abcsdd | Director | 21 Mar 2019 | Past |
| Pramod Abcsdd | Director | 31 Jan 2019 | Past |
| Pramod Abcsdd | Director | 30 Apr 2009 | Past |
Discover detailed profiles of directors and KMP - Unlock leadership insights today!
Time Cap Pharma Labs Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 115818.82% increase. The company also saw a substantial improvement in profitability, with a 115504.51% increase in profit. The company's net worth Soared by an impressive increase of 119272.46%.
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
In 2023, Time Cap Pharma Labs had a public holding of 1.49%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Reveal ownership structures and financial performance - Get instant access now!
₹30,750,000.00
₹0
| Date | Lender | Amount | Status |
|---|---|---|---|
| 09 Dec 1994 | Oriental Bank Of Commerce | ₹1.40 Cr | Open |
| 28 Dec 1992 | Oriental Bank Of Commerce | ₹1.68 Cr | Open |
Explore comprehensive loan charge details -
Time Cap Pharma Labs has a workforce of 2 employees as of Mar 22, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Gain comprehensive insights into the Deals and Valuation data of Time Cap Pharma Labs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Time Cap Pharma Labs's trajectory.
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
Progress on Time Cap Pharma Labs Private Limited last Annual general meeting of members was held on 27 Sep 2025 as per latest MCA records. was documented.
Progress on Time Cap Pharma Labs Private Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Hyderabad. was documented.
Progress on Venkata Satya Swathi Kantamani was appointed as a Whole-time director was appointed as a Whole-time director on 30 Sep 2024 & has been associated with this company since 1 year 2 months . was documented.
Adinarayana Madineedi was appointed as a Director was appointed as a Director on 31 Jan 2019 & has been associated with this company since 6 years 10 months . was recorded as a recent event.
Progress on Sadasiva Rao Nannapaneni was appointed as a Director was appointed as a Director on 30 Apr 2009 & has been associated with this company since 16 years 7 months . was documented.
Anand Babu Tummala was appointed as a Director was appointed as a Director on 29 Apr 2000 & has been associated with this company since 25 years 7 months . was recorded as a recent event.
The Delhi High Court has prohibited Natco Pharma from producing and selling the cancer drug Olaparib, marketed as 'BRACANAT' or under any other name, until further notice. The court's decision came in response to a lawsuit by Kudos Pharmaceuticals, which claimed that Natco was infringing on its patent for Olaparib. The court found Natco's challenge to the patent's validity unconvincing, leading to the injunction. Natco had sought to revoke Kudos' patent only after the lawsuit was filed, despite no previous opposition to it..
The company has launched a generic version of sofosbuvir 400 mg/velpatasvir 100 mg fixed dose combination in India under the brand name 'Velpanat'..
FDA finds procedural and handling gaps in settling plate management in the microbiology and lab employees engaged in the manufacturing and packaging areas require more effective training.Natco to provide due justifications and corrective action plan within the next 15 working days to address the FDA observations.
The CIN of Time Cap Pharma Labs Private Limited is U24232TG1988PTC008333.
Time Cap Pharma Labs Private Limited is headquartered at Natco House , Road No.2 Banjara Hills, Hyderabad, Telangana.
Time Cap Pharma Labs Private Limited was incorporated on 19 February 1988.
The current directors of Time Cap Pharma Labs Private Limited are
The primary industry of Time Cap Pharma Labs Private Limited is Manufacturing.
Time Cap Pharma Labs Private Limited is unlisted.
The authorized capital of Time Cap Pharma Labs Private Limited is ₹1.00 Cr, and the paid-up capital is ₹4.16 M.
The compliance status of Time Cap Pharma Labs Private Limited is Compliant.
Search company & director profiles for free and gain access to critical business data.
Company Details
+91-XXXXXXXXXX